Website
News25/Ratings12
News · 26 weeks630%
2025-10-262026-04-19
Mix4290d
- Other20(48%)
- Insider11(26%)
- Analyst4(10%)
- SEC Filings4(10%)
- Earnings2(5%)
- Offering1(2%)
Latest news
25 items- SECSEC Form DEFA14A filed by Caris Life Sciences Inc.DEFA14A - Caris Life Sciences, Inc. (0002019410) (Filer)
- SECSEC Form DEF 14A filed by Caris Life Sciences Inc.DEF 14A - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion
- PRCaris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer CenterIRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research. "Welcoming UCSF Helen Diller Family Comprehensive Cancer Center to the Caris Precision Oncology Alliance underscores
- PRCaris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer PatientsComprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwideIRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.
- ANALYSTJefferies initiated coverage on Caris Life Sciences with a new price targetJefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00
- ANALYSTPiper Sandler initiated coverage on Caris Life Sciences with a new price targetPiper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00
- PRCaris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC PatientsCaris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC) patients. The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the addition of chemotherapy.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid MalignanciesUltra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insightIRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected mye
- ANALYSTGoldman initiated coverage on Caris Life Sciences with a new price targetGoldman initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $27.00
- PRCaris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris DetectResults demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approachesIRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris' goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test. Caris Detect leverages Caris' industry-leading molecular profiling data, whic
- PRCaris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung CancerCaris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panelsIRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumor Board Report. These signatures assess the risk of patients developing brain metastases in breast and lung cancer. The addition of these two signatures brings the total number of proprietary Caris AI insights to seven, providing deeper insights to physicians and patients. This report, avail
- PRCaris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026. These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcrip
- PRCaris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness MonthCaris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patientsIRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing Colorectal Cancer Awareness Month by highlighting the critical role of DPYD testing in helping to inform treatment for patients with colorectal cancer. Colorectal cancer remains one of the most commonly diagnosed cancers in the United States and is a leading cause of cancer-relat
- PRCaris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer PatientsHighlighting the critical role of Caris GPSai in improving cancer careIRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types.
- PRCaris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian CancerCaris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.
- PRCaris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual MeetingIRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026. Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was u
- INSIDERPresident Spetzler David Baxley was granted 83,162 shares, increasing direct ownership by 18% to 543,939 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERSEC Form 4 filed by Caris Life Sciences Inc.4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Denton John Russel was granted 63,971 shares, increasing direct ownership by 52% to 187,562 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERSEC Form 4 filed by Caris Life Sciences Inc.4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Brille Brian J was granted 83,162 shares, increasing direct ownership by 52% to 244,290 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- PRCaris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic CancerCaris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative tumor profiling report that provides an additional tumor biology resource and is available upon request with no additional tissue sampling required when ordering MI Cancer Seek®.